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The role of aldosterone in extrarenal potassium tolerance: Studies in
anephric man. Since the role of aldosterone in mediating extrarenal
potassium transport remains uncertain, the effect of mineralocorticoid
on potassium metabolism was assessed in anephric patients. Seven
anephric patients underwent three identical 72-hour periods between
hemodialyses during which treatment with either 10 mg/day deoxycor-
ticosterone acetate (DOCA) intramuscularly or 300 mg/day spirono-
lactone orally was compared to a baseline control period. The serum
potassium rise, plasma aldosterone, salivary and stool electrolytes were
measured in response to potassium loading over 48 hours with a
metabolic diet containing 38 mEq/day followed by an "acute" oral
potassium load of 0.5 mEq/kg. Acute potassium loading with DOCA
resulted in a lower increment in serum potassium than with spirono-
lactone (P < 0.01). The volume of distribution of the acute potassium
load at three hours was 55% of body weight with DOCA, which was
significantly greater (P < 0.05) than with either spironolactone (35%) or
control (34%). However, with the dietary load of potassium, the
increments in serum potassium measured at 24 and 48 hours (13 hours
post-prandial) were similar in all three periods. The volume of distri-
bution of the dietary potassium was not altered by DOCA or
spironolactone but had risen to an average of 172% at 24 hours and
243% at 48 hours in the three periods. Plasma aldosterone levels were
low, positively correlated to the serum potassium and similar in all three
periods without evidence of feedback inhibition by DOCA or stimulated
by spironolactone. The salivary potassium was high despite low aldo-
sterone levels. Salivary and stool sodium and potassium concentrations
were unaltered by DOCA or spironolactone. Stool potassium excretion
was approximately 10% of daily intake and consequently failed to serve
as a major route for potassium disposal. In conclusion, the rate of
removal of an acute oral potassium load from the extracellular fluid is
enhanced by a mineralocorticoid, suggesting that aldosterone may be
important in mediating acute elevations in serum potassium in anephric
man. The administration of a dietary potassium load of comparable size
results in a much greater sequestration of potassium outside of the
extracellular fluid. This enhanced transfer does not appear to be
affected by DOCA or spironolactone as reflected by serum potassium
levels measured at 24 and 48 hours. This would suggest that the activity
of aldosterone in improving extrarenal potassium tolerance is greatest
within the first few hours of potassium administration.
The defense against hyperkalemia involves the activation of
both renal and extrarenal mechanisms. Aldosterone has been
demonstrated to participate in renal potassium excretion by its
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action on the distal tubule and collecting duct. Although its role
in mediating extrarenal potassium transport has been studied in
detail in vitro [1, 2] and in animal models [3—7], its relative
importance in facilitating the extrarenal disposal of acute po-
tassium loads out of the extracellular fluid compartment has not
been clearly defined, particularly in man. Some studies carried
out in animals [4, 5] and normal human subjects [8] failed to
demonstrate a role for aldosterone in mediating extrarenal
potassium disposal. Other studies conducted in chronically
adrenalectomized rats [6, 7] and in patients with the syndrome
of hyporeninemic hypoaldosteronism [9, 10] suggest that aldo-
sterone and mineralocorticoids enhance the net transfer of
potassium from the extracellular fluid.
Patients with chronic renal failure have low ratios of sodium
to potassium in the saliva [11] and in the stool [12] as seen in
patients with hyperaldosteronism [13—16]. This has been ac-
companied by enhanced fecal potassium excretion [17, 18],
suggesting that aldosterone may be mediating both the salivary
electrolyte composition and the increased intestinal potassium
loss. Alternatively, other studies have demonstrated that aldo-
sterone may not be contributing to the enhanced fecal potas-
sium excretion in rats [19], and plasma aldosterone levels have
been found to fall within normal limits in many patients with
renal impairment [20]. The present studies were therefore
carried out in anephric patients, in whom aldosterone and renin
levels are expected to be low, in order to further examine the
role of aldosterone in modulating the extrarenal disposition of
acute and dietary potassium loads in humans.
Methods
Seven patients (5 males, 2 females; ages 19 to 65 years) with
end-stage renal disease who had undergone prior bilateral
nephrectomy for the control of hypertension or in preparation
for a kidney allograft were studied. All were being treated with
maintenance hemodialysis three times each week and were not
diabetic. All studies were performed in the Charles A. Dana
Clinical Research Center of Harvard Medical School at the
Beth Israel Hospital, and were approved by the Committee on
Human Investigation, New Procedures and New Forms of
Therapy of Beth Israel Hospital.
Study protocol
Each patient was placed on a strict metabolic diet containing
2,000 calories, 60 g of protein, 87 mEq of sodium and 38 mEq of
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Fig. 1. Schematic diagram of the study
protocol in seven anephric patients. The
dietary potassium load consisted of 38 mEq
per day of potassium in a metabolic diet, 76
mEq total over 48 hours, from 8 a.m. of the
first morning to 8 a.m. of the third morning
after the initial hemodialysis. Thereafter, an
"acute" potassium load of 0.5 mEq per kg
body weight of potassium chloride was given
orally over five minutes with measurements
continued for three hours before the
concluding hemodialysis. This pattern was
followed in each of the three interdialytic
periods: the control period on no medications,
the DOCA period (10 mg intramuscularly
daily) and the spironolactone period (300 mg
daily as 100 mg orally every 8 hours),
potassium each day. The study protocol consisted of three
interdialytic periods of three days each, as outlined in Figure 1.
Each period began with an initial hemodialysis in the afternoon,
followed by daily measurement of serum electrolytes, glucose,
urea nitrogen, and venous blood pH at 8:00 a.m., 13 hours
following the prior dinner meal. Plasma cortisol levels were
drawn on the first morning and plasma renin activity and
aldosterone were drawn each morning while the patient re-
mained in the recumbent position. Samples of paraffin stimu-
lated saliva were taken each morning and all stools were
collected for sodium and potassium determinations. After over-
night equilibration from dialysis, a 48 hour period of dietary
potassium loading took place from 8:00 a.m. on the first
morning to 8:00 a.m. on the third morning following the iflitial
hemodialysis. Thereafter, an "acute" oral load of potassium
chloride (Kay Ciel Powder in 10% sugar-free aqueous solution,
Berlex Laboratories, Inc., Wayne, New Jersey, USA) contain-
ing 0.5 mEq per kg body weight was administered over five
minutes if the serum potassium was less than 6 mEq/liter. The
electrocardiogram was monitored continuously during this
phase of the study. Serial serum potassium levels were drawn
every thirty minutes, and blood pH and aldosterone levels were
measured every 60 minutes for a total of 180 minutes. At the
termination of this three hour period each patient underwent a
second hemodialysis concluding the period.
After the first or "control" period on no medications, the
second three-day study period was carried out in identical
fashion except for the administration of deoxycorticosterone
acetate (DOCA, 10 mg intramuscularly) daily during each of the
three interdialytic days starting immediately following the initial
hemodialysis. DOCA was selected because it is virtually devoid
of any glucocorticoid activity [21]. The DOCA dose of 10
mg/day was based on a normal aldosterone secretory rate of
from 50 to 250 p.g/day and relative mineralocorticoid activity
potency of aidosterone to DOCA of from 20-100 to 1 which
would result in a physiologic DOCA dose range of about ito 25
mg/day [21—23]. The third study period followed the identical
protocol of chronic and acute potassium loading except that
spironolactone 100 mg orally every eight hours was given
instead of DOCA (Fig. 1). The three study periods were
separated by non-study interdialytic periods in five of the seven
patients.
Analytical methods
Serum and salivary sodium and potassium were measured
with a flame photometer with lithium as the internal standard.
Stool sodium and potassium were determined by blending 10 g
of fecal material with 10 ml of distilled water. The homogenate
was then centrifuged and the sodium and potassium were
determined from the supernatant with the flame photometer.
Serum urea nitrogen, chloride and bicarbonate were measured
on a Technicon Auto Analyzer (Technicon Instruments Corp.,
Tarrytown, New York, USA); venous pH was measured by
blood gas analyzer (Instrumentation Laboratory, Lexington,
Massachusetts, USA). Plasma renin activity was measured by
radioimmunoassay of angiotensin I [24] and plasma aldosterone
by radioimmunoassay (antibody furnished by Dr. James Melby)
which did not detect deoxycorticosterone acetate [25].
Statistical methods
Statistical analysis was carried out by the General Linear
Models Procedure of Statistical Analysis System [26]. Results
are based on repeated measurements analysis, and randomized
block analysis of variance. Subsequent to the overall analysis,
pairwise differences were evaluated using a T statistic carried
out in a nonsimultaneous manner with the estimate of error
derived from the overall analysis. In addition, Student's i-test
was used wherever applicable. Results are expressed as means
SE.
Results
The results of the acute oral potassium chloride load for
successfully completed studies in six patients during the control
and DOCA periods and in five patients for the spironolactone
period are shown in Figure 2. The mean serum potassium
following the potassium chloride load is plotted over 180
minutes in each of the three study periods. The initial serum
potassium level of 5.3 mEq/liter after the dietary loading but
before the administration of the potassium load was similar in
each period. The repeated measurements and randomized block
analysis indicated that at least one of the three treatment groups
was significantly different from the others with respect to
change averaged over all time points (P < 0.05). The pairwise T
tests pet-formed subsequent to the overall analysis also with
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Fig. 2. Effect on serum potassium levels over 180 minutes following the
administration of an acute oral potassium load of 0.5 mEq/kg during
control (0), DOCA (•), and spironolactone (A) periods in 6 anephric
subjects (5 in the spironolactone period). The DOCA and spironolac-
tone plots differ from each other (P < 0.01) whereas the DOCA and
spironolactone plots each differ from control (P = 0.05).
Table 1. Mean rise in serum potassium and the apparent volume of
distribution resulting from dietary potassium loading of 38 mEq per
day over 48 hours during control, DOCA, and spironolactone periods
in anephric subjects
Mean rise in serum Volume of
potassium distribution
mEqiliter % body weight
Period N 24 hr 48 hr 24 hr 48 hr
Control 7 0.44 0.11 0.66 0.12 146 43 202 36
DOCA 6 0.35 0.09 0.60 0.14 209 55 281 110
Spironolactone 7 0.29 0.03 0.56 0.08 161 II 245 62
respect to change averaged over all time points, revealed that:
a) the rise of serum potassium with DOCA was significantly less
than with spironolactone (P < 0.01); b) the rise of potassium
with DOCA was less and with spironolactone was greater than
control (P = 0.05 for each test).
In Table 1 the mean rise of serum potassium induced by
dietary potassium loading of 38 mEq/day is shown over each of
the two days, from the first to the third morning after the initial
hemodialysis in the seven patients (one patient did not undergo
the DOCA period study). The rise of serum potassium mea-
sured 13 hours post-prandially was 0.44 0.11 mEq/liter after
the first day and 0.66 0.12 mEq/liter after two days in the
control period. The rise of serum potassium was not affected by
either DOCA or spironolactone administration. Therefore by 13
hours after the last ingested portion of dietary potassium, no
differences in the rise in serum potassium among the three
periods were observed.
The apparent volume of distribution of the acute oral and
dietary potassium loads was calculated as the quantity of
potassium administered divided by the increment in plasma
potassium and expressed as a percent of body weight. The
quantity of potassium administered during the chronic 24 and 48
hour periods was calculated as the difference between dietary
potassium intake and stool loss. These results are shown in
Table 2. Mean rise in serum potassium and the apparent volume of
distribution at 3 hours after an acute oral potassium load of 0.5 mEq
per kg body weight during control, DOCA, and spironolactone
periods in anephric subjects
Mean rise in Volume of
serum potassium distribution
Period N mEq//iter % body wt
Control 6 1.40 0.07 34 2
DOCA 6 1.07 0.l9a 55 ba
Spironolactone 5 1.50 0.27 35 6
0 2 4 6 8
Serum K, mEqi/iter
Fig. 3. The relationship between plasma aldosterone and serum potas-
sium during control, DOCA and spironolactone periods in 7 anephric
patients (6 in the DOCA period). Each line is derived from 34 to 38
measurements of simultaneous plasma aldosterone and serum potas-
sium during chronic and acute potassium loading. The slopes and
intercepts of the 3 lines are not significantly different from each other.
Tables 1 and 2. During the acute potassium loading the mean
volume of distribution was calculated for the peak increment in
serum potassium at 180 minutes, since the rise in serum
potassium appeared to have reached a plateau by that time in all
three study periods (Fig. 2). Results for the control, DOCA, and
spironolactone periods were 34, 55, and 35% of body weight,
respectively (Table 2). The volume of distribution of potassium
in the DOCA period was significantly greater than in the
spironolactone (P < 0.05) and control periods (P <0.05), but
the latter two periods were insignificantly different from each
other. The volume of distribution of the dietary potassium load
at 24 and 48 hours was much increased over that of the acute
load, equaling 202, 281 and 245%, respectively at 48 hours in the
control, DOCA and spironolactone periods without any signif-
icant differences among the periods (Table 1).
The relation between plasma aldosterone levels and simulta-
neous serum potassium in each of the three periods is illustrated
in Figure 3. Each line is derived from 34 to 38 measurements
and documents a positive correlation of plasma aldosterone to
the rising serum potassium induced by the dietary potassium
and the oral potassium load. The aldosterone level at a normal
serum potassium of 4.0 mEq/liter in the anephric subjects is low
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Table 3. Initial values and changes in venous pH and bicarbonate levels associated with acut
DOCA, and spironolactone periods
e and dictary potassium bading during control,
Period N
.Initial Change
pH in pH N
Initial
bicarbonate
Change in
bicarbonate
inEqlliter
Acute
potassium
load
Control
DOCA
Spironolactone
5
5
4
7.31 0.01
0.02 0.01
7.32 +0.01 0.04
6
6
5
19.0 0.9
20.7 1.1
18.4 1.1
—2.8 1.0
—2.8 1.7
—2.6 1.3
Chronic
potassium
load
Control
DOCA
Spironolactone
6
5
6
7.34 0.01 —0.03 0.02
7.37 0.03 —0.06 0.03
7.36 0.01 —0.06 0.02
7
6
7
23.7 0.8
25.3 0.9
21.7 1.6
—4.0 0.6
—4.8 1.3
—3.9 0.8
Changes in pH and bicarbonate are over 180 minutes for the acute potassium load and over 48 hours for the dietary potassium load; pH values
were not available for one subject in all periods. Differences among related values are not significant.
Table 4. Mean salivary sodium and potassium concentrations and
cumulative stool sodium and potassium excretion over each 72 hour
study period for the control, DOCA, and spironolactone periods
Period N
Saliva
Na K
mEqiliter
Control 7 14.4 3.5 23.0 5.0
DOCA 6 13.5 4.7 23.8 1.1
Spironolactone 7 16.1 3.7 25.9 1.5
Normal levels (adapted from 20—80 10—20
ref. 26)
N
Stool
Total 72 hr Na Total 72 hr K
mEq
Control 7 3.2 1,5 9.2 3,4
DOCA 6 5.7 2.1 13.8 1.5
Spironolactone 7 5.8 3.1 12.1 2.4
Normal levels (adapted from 1—8 mEq/24 hr 2—18 mEq/24 hr
ref. 27)
Normal levels are given for comparison. Differences among related
values are not significant.
in each period when compared to a supine aldosterone of 5 to 15
ng/100 ml in normal subjects in our laboratory. Furthermore,
the addition of DOCA which would normally cause suppression
of aldosterone by negative feedback inhibition in the renal
intact state or the addition of spironolactone which would
normally increase aldosterone failed to alter the relationship
between aldosterone and potassium concentration in these
patients. Plasma renin activity was very low (<0.5 ng angioten-
sin lJmlJhr) or undetectable in all patients, and was not signifi-
cantly influenced by the different study protocols. Plasma
cortisol levels were within normal limits in all studies, indicat-
ing that in these patients who had undergone bilateral nephrec-
tomy, adrenal glucocorticoid function was conserved. Values
for venous pH and bicarbonate levels are summarized in Table
3. There were no significant differences in the changes in
venous pH or bicarbonate levels among the three periods of
acute and dietary potassium loading.
The salivary and fecal sodium and potassium concentrations
are summarized in Table 4. The saliva was shown to have low
sodium and high potassium concentrations when compared to
normal subjects [27] and which are thought to reflect the effect
of aldosterone on the salivary glandular secretions [13, 14].
However, the salivary electrolyte composition was unaffected
by the addition of either DOCA or spironolactone to these
patients with low aldosterone levels. The fecal sodium and
potassium were within normal limits in all three periods [28]
with no significant difference among periods. Total fecal elec-
trolyte excretion shown cumulatively over each three day
period was also unaffected by either DOCA or spironolactone.
Fecal potassium excretion, while amounting to almost twice
that of sodium, averaged below 4 mEq/day, primarily due to the
small volume of hard stools excreted by these patients (possibly
due to constipation from aluminum hydroxide taken by all
patients prior to the study).
Discussion
The role of aldosterone as one of the potential mediators of
extrarenal potassium transport has received a considerable
amount of attention in the literature. In vitro studies with
aldosterone have yielded conflicting results showing either
enhanced net cellular uptake [1] or accelerated net cellular
efflux [2] of potassium. The administration of acute potassium
loads immediately following adrenalectomy in dogs [5] and cats
[29] has demonstrated impaired potassium tolerance, but with
conflicting results reported in studies of acutely adrenalecto-
mized rats [30, 31]. This may be related to the persistent
biological activity of aldosterone post-adrenalectomy [21].
Chronically adrenalectomized rats maintained on very high
doses of DOCA in one study demonstrated an enhanced toler-
ance to an acute potassium load [3]. Moreover, it has been
shown that rats with chronic adrenal insufficiency maintained
on glucocorticoids displayed an impaired tolerance to an acute
potassium load [6, 7] which was improved by the administration
of either epinephrine or aldosterone [7]. However, when acute
potassium loads were given to four normal human subjects
treated with aminoglutethimide, an inhibitor of aldosterone
biosynthesis, the subsequent rise in plasma potassium was not
different from control, although their plasma levels of aldoste-
rone were barely detectable [81. These data may suggest that
tolerance to an acute potassium load in normal man is not
dependent on aldosterone.
The present studies demonstrate that in the anephric patient,
the addition of exogenous minerabocorticoid over a 60 hour
period prior to the introduction of an acute oral potassium load
decreased the rate of rise in serum potassium compared to a
control period (Fig. 2). The basal plasma aldosterone levels in
Sugarman and Brown: Aldosterone and extrarenal K tolerance 401
these patients with little or no renin activity were found to be
low, despite elevated basal potassium levels, a finding which
has been previously noted in other studies of anephric subjects
[32, 33]. We therefore selected a mineralocorticoid which has
virtually no glucocorticoid activity, DOCA, administered at a
replacement dose which was equivalent in mineralocorticoid
activity to the mid-range of levels of aldosterone in normal
subjects. The addition of DOCA may, however, indicate that
supra-physiologic quantities of mineralocorticoid are required
to enhance the net transport of an acute potassium load out of
the extracellular fluid. But in the spironolactone study period, it
was observed that blocking the activity of even these low
circulating levels of aldosterone resulted in a higher rate of rise
in plasma potassium after the acute potassium load than in the
control period. Since the rate of rise of potassium during the
administration of mineralocorticoid is significantly lower than
that observed when the activity of this hormone is suppressed
with spironolactone, aldosterone appears to play an important
role in the extrarenal modulation of an acute potassium load in
anephric man.
During the control period the acute potassium load had a
volume of distribution of 34% of body weight, somewhat less
than total body water, and lower than the volume of distribution
of comparable amounts of potassium infused intravenously
over similar periods of time to normal subjects and anuric
patients with kidneys in other studies [34-36]. Whereas DOCA
significantly increased the volume of distribution of the acute
potassium load, the volume of distribution during spirono-
lactone was not significantly different from control. Although
spironolactone seemed to augment the rate of rise of potassium
calculated from all time points (Fig. 2), the volume of distribu-
tion calculated at 180 minutes was no different from control
(Table 2). This finding may indicate that spironolactone did not
change the final potassium level. However, an alternative
explanation may be based upon the lOw plasma aldosterone
levels observed in these anephric patients compared to those
reported for normal subjects receiving similar potassium loads
[34, 35]. Antagonism by spironolactone of these low levels of
aldosterone may have caused too small an impact on extrarenal
potassium disposal to persist after three hours when compared
to control values. The effect of spironolactone to diminish acute
potassium disposal is certainly apparent when compared to the
DOCA period in which mineralocorticoid activity has been
increased up to or above the range of normal subjects. The
administration of mineralocorticoid to patients on hemodialysis
may therefore be of therapeutic value in blunting the acute rise
in serum potassium resulting from indiscretions in dietary
potassium intake, as has been shown in two anephric and five
anuric patients treated with fludrocortisone, 0.4 to 0.6 mg per
day, in two studies [37, 38].
The oral route of potassium administration was selected
because it approximates a dietary potassium load. Since the rise
of serum potassium was greater and the apparent volume of
distribution was smaller in these anephric patients than in
normal or anuric subjects receiving intravenous potassium
loads [34—36], it seems less likely that any significant quantity of
potassium was sequestered in the gastrointestinal tract. How-
ever, this study cannot rule out differences in the rate of
potassium absorption by the gastrointestinal tract among the
study periods. The findings of a plateau of the serum potassium
from 120 to 180 minutes after each of the acute loads and of
similar stool potassium contents in each period support an
assumption that an enhanced rate of cellular uptake of potassi-
um, rather than a decreased rate of net gastrointestinal absorp-
tion, explains the mineralocorticoid effect.
Since the mean weight of the seven patients under study was
65 5 kg, the quantity of potassium in the acute oral load (0.5
mEq/kg) was roughly comparable to that of the three meals of
the dietary load (38 mEq/day). In contrast to the acute load,
however, the 24 and 48 hour increments in serum potassium
(measured 13 hours following the last previous meal) were
found to be similar among the three periods without a discern-
ible effect of aldosterone. These findings would suggest that the
salutory effect of aldosterone on extrarenal potassium disposal
in these studies is lost between 3 and 13 hours after oral
ingestion of a potassium load. However, potassium continues to
be translocated out of the extracellular fluid as evidenced by the
marked increases in the volumes of distribution of the dietary
potassium at 24 and 48 hours, averaging 172 and 243% of body
weight, respectively, when compared to the average of only
41% at three hours after the acute load (Tables 1 and 2). It is
possible that more frequent measurements of the serum potas-
sium would have revealed that during a large portion of the
postprandial period the potassium levels were in fact lower than
control when DOCA was administered. The enhanced extrare-
nal potassium disposal observed at 24 and 48 hours would then
be consequent to the persistent but progressively diminishing
effect of aldosterone in mediating this transfer. Alternatively, it
may be that dietary stimulation of insulin release, as well as the
increased catecholamine activity induced by eating [39] contrib-
uted to the enhanced net movement of potassium out of the
extracellular fluid [6, 30, 34] and thereby obscured the persist-
ent effect of aldosterone. There were no changes in the venous
pH or the serum bicarbonate among the periods that could
explain the differences in potassium tolerance.
In the present studies aldosterone levels were found to be
linearly related to plasma potassium concentration during all
three study periods and during both acute and chronic potas-
sium administration. In subjects with normal kidney function,
however, the salt and water retention induced by DOCA would
normally suppress aldosterone via feedback inhibition of the
renin angiotensin system, and the salt and water loss induced by
spironolactone would stimulate aldosterone secretion by the
opposite mechanism. The present studies demonstrate that in
the anephric state when this feedback ioop is inoperative, the
addition of either DOCA or spironolactone fails to alter the
aldosterone to potassium relationship, and support the findings
of previous studies that in the anephric state with low or absent
renin and angiotensin II, plasma potassium is the primary
modulator of aldosterone secretion [33, 40].
Despite the low plasma aldosterone levels in these patients,
the salivary sodium concentration was low and potassium was
high when compared to normals [27] and were in the range
commonly associated with primary or secondary hyperaldoste-
ronism [13, 14]. Since potassium adaptation has already been
shown to induce increased tubUlar Na-K-ATPase activity and
potassium secretion in the kidney independent of any mm-
eralocorticoid effect [41], it is possible that this finding may
reflect a similar potassium adaptation of the salivary gland to
chronic potassium loading. The addition of DOCA or spirono-
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lactone had no effect on the salivary electrolyte composition,
another finding suggestive that a direct potassium effect inde-
pendent of aldosterone may be operative.
Studies in the rat have shown that chronic renal insufficiency
is associated with an adaptive mechanism at the level of the
colon for increased rates of potassium secretion [18]. Patients
with chronic renal failure have low sodium and high potassium
concentrations in fecal dialysate [12], and increased potassium
secretion in the stool [17]. This enhanced capacity for potas-
sium secretion is also observed with normal renal function in
response to elevated levels of mineralocorticoids [15, 16]. It has
been suggested that aldosterone may be playing a role in
mediating the adaptive response by the colon in chronic renal
failure as well.
In the present studies fecal sodium and potassium excretion
were within the normal range (Table 4). However, these studies
were conducted in patients who had been receiving aluminum-
containing phosphate binding gels prior to the onset of the study
periods, and consequently produced small quantities of hard
stool. By contrast, the increased fecal potassium excretion data
of the earlier human studies were derived from the examination
of either colonic fluid [16] or soft stool [17], with the potassium
excretion in the latter study being directly related to the wet
weight of the stool. Therefore it is possible that the enhanced
ability of the colon in chronic renal failure to excrete potassium
is impaired in the present studies by the prior use of phosphate
binding gels. Although chronic dialysis patients who produced
soft stool have been reported to excrete up to 37% of their
dietary potassium intake [17], fecal potassium excretion in the
present studies averaged about 4 mEq/day (approximately 10%
of intake) and therefore failed to serve as a useful route for
potassium disposal.
In addition these studies reveal that fecal electrolyte excre-
tion shown over the whole three day period was unaffected by
either DOCA or spironolactone. Since stool markers were not
used, it is possible that incomplete collections or overlap of
stool among the collection periods may have occurred. How-
ever, the same pattern of fecal sodium and potassium was
observed in every patient during each study period representing
12 to 25 stool collections per period. Moreover, this pattern did
not differ from one period to another even when the periods
were not consecutive, suggesting that under the present study
conditions aldosterone was not an important factor in the fecal
excretion of these electrolytes. This is in agreement with a
study which noted that the average percent excretion of dietary
potassium in chronic renal failure patients appeared unaltered
by an increased dietary intake of sodium or by the administra-
tion of either spironolactone or chlorothiazide [17]. Similarly, it
has been reported that colonic potassium adaptation in potas-
sium loaded rats occurred even when the animals were adre-
nalectomized and maintained with physiologic amounts of
glucocorticoids [19]. Also, it has been shown that spironolac-
tone resulted in an insignificant decrease in colonic potassium
secretion in intact rats [42].
In summary, our data show that the rate of rise of the serum
potassium following an acute potassium load was decreased by
the addition of DOCA and increased by spironolactone. These
results suggest that aldosterone plays a role in modulating acute
extrarenal potassium tolerance in anephric patients, either by
an enhanced rate of cellular uptake, or possibly a reduced rate
of gastrointestinal absorption, of potassium. However, a di-
etary potassium load over 48 hours is accompanied by about a
six-fold increase in the apparent volume of distribution of
potassium compared to the acute load. This enhanced net
transfer of potassium from the extracellular fluid may be
mediated by aldosterone acting primarily within the first few
hours of potassium ingestion, or quite likely, by recruitment of
factors other than aldosterone which improve extrarenal potas-
sium tolerance. These studies confirm that anephric patients
have low levels of plasma aldosterone which are positively
correlated to the serum potassium and not affected by the
addition of DOCA or spironolactone. Despite the low aldoste-
rone levels, salivary potassium to sodium ratios remained high,
as commonly seen with hyperaldosteronism. The addition of
either DOCA or spironolactone failed to alter salivary or stool
potassium. The low total fecal potassium excretion during each
of the study periods would indicate that under these conditions
the gastrointestinal tract does not play a major role in potassium
excretion and is unaffected by aldosterone.
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